Clinical Trials Browser

Phase 2 × Lung Neoplasms × Poly(ADP-ribose) Polymerase Inhibitors × Clear all

NCT05392686 2022-05-26

PD1 and PARP for Maintenance Therapy in NSLLC

Phase 2 Unknown

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms